Dynavax Technologies Corporation (NASDAQ:DVAX) will be releasing its earnings data before the market opens on Monday, November 6th. Analysts expect Dynavax Technologies Corporation to post earnings of ($0.53) per share for the quarter.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. During the same quarter last year, the company earned ($0.75) EPS. On average, analysts expect Dynavax Technologies Corporation to post $-1.74 EPS for the current fiscal year and $-1.27 EPS for the next fiscal year.

Dynavax Technologies Corporation (DVAX) opened at 21.70 on Monday. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $24.45. The firm’s 50-day moving average price is $21.42 and its 200-day moving average price is $12.90. The company’s market cap is $1.19 billion.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/30/dynavax-technologies-corporation-dvax-to-release-earnings-on-monday.html.

DVAX has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Monday, July 10th. Royal Bank Of Canada set a $7.00 target price on shares of Dynavax Technologies Corporation and gave the company a “hold” rating in a report on Wednesday, July 26th. William Blair reissued an “outperform” rating on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Cowen and Company reissued an “outperform” rating and set a $45.00 target price on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $6.00 to $27.00 in a report on Monday, July 31st. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $25.00.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Earnings History for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.